期刊文献+

复合阿伦磷酸钠骨水泥对成骨细胞的影响 被引量:2

Effect of alendronate-loaded bone cement on osteoblast
下载PDF
导出
摘要 目的:研究不同阿伦磷酸钠含量的骨水泥对成骨细胞的影响,确定复合阿伦磷酸钠骨水泥的细胞毒性.方法:根据阿伦磷酸钠含量不同分成6组,在50 g Cemex*XL骨水泥粉末中分别加入0,10,50,100,500,1 000 mg阿伦磷酸钠,依次命名为G0~G5组.通过电镜观察各组成骨细胞样MG-63的黏附能力,MTT比色法测定吸光度值,碱性磷酸酶试剂盒测定碱性磷酸酶(alkaline phosphatase activity,AKP)活性,Annexin-V-FITC凋亡检测试剂盒测定凋亡率,相差显微镜观察骨矿化情况.结果:各组MG-63细胞黏附能力良好;与Go组相比,G1~G4组抑制细胞凋亡,G5组促进细胞凋亡和抑制细胞增殖(p<0.05);各组特异性碱性磷酸酶活性、骨矿化能力差异无统计学意义(p>0.05).结论:在50 g骨水泥粉末中加入阿伦磷酸钠不超过500 mg对成骨细胞无毒性. Objective: To determine the effect of bone cement, with different amounts of alendronate on osteoblast, and determine the cytotoxicity of alendronate-integrated bone cement from the viewpoint of cell biology. Methods: According to dif erent additions(0, 10, 50, 100, 500, 1 000 mg) of alendronate in 50 g Cemex?XL bone cement powder, the experiments were divided into 6 groups, namely G0–G5 groups. In all groups, the adhesive capacity of osteoblast-like cells MG-63 was evaluated by electron microscope, the optical density(OD) value of cells by MTT colorimetry method, the alkaline phosphatase activity(AKP) by AKP assay kit, the apoptosis rates by Annexin-V-FITC apoptosis detection kit, and the bone mineralization potentiality by phase contrast microscope. Results: h e adhesive capacity of MG-63 was good in all groups. Compared with the G0 group, the cell apoptosis was inhibited in G1–G4 groups while in G5 group the cell apoptosis was promoted and cell proliferation was inhibited(P<0.05). In all groups, no signii cant dif erence was found in alkaline phosphatase activity and bone mineralization potentiality(P>0.05).Conclusion: Less than 500 mg alendronate added in Cemex?XL 50 g bone cement powder has no cytotoxicity on osteoblasts.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2014年第3期290-295,共6页 Journal of Central South University :Medical Science
关键词 阿伦磷酸钠 二磷酸盐 含量 骨水泥 成骨细胞 alendronate bisphosphonate amount bone cement osteoblast
  • 相关文献

参考文献16

  • 1Hu X,Neoh KG,Shi Z. An in vitro assessment of fibroblast and osteoblast response to alendronate-moditied titanium and the potential for decreasing fibrous encapsulation[J].Tissue Engineering Part A,2013,(17/18):1919-1930.
  • 2Kim SE,Suh DH,Yun YP. Local delivery of alendronate eluting chitosan scaffold can effectively increase osteoblast functions and inhibit osteoclast differentiation[J].Journal of Materials Science: Materials in Medicine,2012,(11):2739-2749.
  • 3Hayden RS,Vollrath M,Kaplan DL. Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films[J].ACTA BIOMATERIALIA,2014,(01):486-493.
  • 4Jobke B,Milovanovic P,Amling M. Bisphosphonate-osteoclasts:changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients[J].BONE,2014.37-43.
  • 5Balena R,Toolan BC,Shea M. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism,bone histomorphometry,and bone strength in ovariectomized nonhuman primates[J].Journal of Clinical Investigation,1993,(06):2577-2586.
  • 6Storm T,Steiniche T,Thamsborg G. Changes in bone histomorphometry after long-term treatment with intermittent,cyclic etidronate for postmenopausal osteoporosis[J].Journal of Bone and Mineral Research,1993,(02):199-208.
  • 7Im GI,Qureshi SA,Kenney J. Osteoblast proliferation and maturation by bisphosphonates[J].BIOMATERIALS,2004,(18):4105-4115.
  • 8Mathov I,Plotkin LI,Sgarlata CL. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro[J].Journal of Bone and Mineral Research,2001,(11):2050-2056.
  • 9Viereck V,Emons G,Lauck V. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts[J].Biochemical and Biophysical Research Communications,2002,(03):680-686.
  • 10Miiller-Rath R,Wirtz DC,Siebert CH. Amphiphilic bonder improves adhesion at the acrylic bone cement-bone interface of cemented acetabular components in total hip arthroplasty:in vivo tests in an ovine model[J].Archives of Orthopaedic and Trauma Surgery,2008,(07):701-707.

二级参考文献18

  • 1Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone, 1999, 25: 97-106.
  • 2Fleisch HA. Bisphosphonates in Bone Disease. From the Laboratory to the Patient (3rd Ed. ed. ). Parthenon, New York (1997).
  • 3Francis RM. Bisphosphonates in the treatment of osteoporosis in 1997: a review. Curr Ther Res, 1997, 58: 656-678.
  • 4Fleisch HA. Bisphosphonates: mechanisms of action. Endocrine Rev, 1998, 19: 80-100.
  • 5Rodan GA, Fleisch HA. Bisphosphonates : mechanism of action. J Clin Invest, 1996, 97 : 2692-2696.
  • 6Fleisch HA. Bisphosphonates: mechanisms of action. Endocr Rev, 1998, 19: 80-100.
  • 7Bone HG, Hosking D, Devogelaer JP, et al. Ten year's experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med, 2004, 350:1189-1199.
  • 8Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int, 2004, 15:792-798.
  • 9Harris ST, Watts NB, Genant HK, et al. Effects of risedmnate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc, 1999, 282 : 1344-1352.
  • 10Rodan G, Alfred R, Ellis G, et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin, 2004, 20 : 1291- 1300.

共引文献2

同被引文献7

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部